Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no known direct pharmacokinetic interaction between semaglutide and testosterone, and the two are not contraindicated together in UK clinical guidance. That said, how each affects the other in practice is a more layered question than a simple yes or no. Semaglutide — the active ingredient in Wegovy — is a prescription-only medicine, and any decision about combining it with testosterone therapy requires a prescriber to review the full clinical picture, including your current treatment, dose and health background.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
UK prescribing information for semaglutide does not list testosterone as a contraindicated medicine, and no major drug interaction has been identified in the product's pharmacokinetic studies. The NHS medicines page for semaglutide sets out a list of medicines to discuss with your prescriber before starting, and testosterone is not among the flagged categories. That is genuinely reassuring, though it is not the whole story.
What the evidence does show clearly is that semaglutide slows gastric emptying, particularly in the early weeks of treatment. This can reduce the rate at which orally administered medicines are absorbed, not by blocking absorption, but by altering the timing. Oral testosterone preparations may therefore be affected. Injectable testosterone formulations bypass the gut entirely and are not subject to this mechanism, which is why the form of testosterone therapy matters.
The SURMOUNT and STEP trial programmes, cited in NICE's appraisal of semaglutide (TA875), were not designed to examine hormone therapy interactions, so there is no large-scale randomised evidence on this specific combination. Clinicians working in obesity medicine draw on pharmacokinetic principles and case-level monitoring rather than a dedicated trial dataset. That gap in the literature is itself a reason to keep your prescriber informed.
Obesity is associated with lower testosterone levels in men. Adipose tissue converts androgens into oestrogens via aromatase, and higher body fat generally correlates with lower circulating testosterone. This is well established in endocrinology research, and it is a clinically significant detail if you are on testosterone replacement therapy and also starting semaglutide treatment.
As semaglutide reduces body weight, particularly fat mass, endogenous testosterone production can recover. Several studies have documented meaningful rises in testosterone in men who lose significant amounts of weight. If you are already receiving exogenous testosterone, this recovery can push levels higher than expected, and your dose may need downward adjustment.
The practical consequence: if you take Wegovy and testosterone together, your testosterone levels should be monitored more actively than they would be for either treatment alone. This is not a reason to avoid the combination, it is a reason to manage it properly. Our page on how semaglutide affects testosterone levels covers the hormonal mechanisms in more detail, including what the observational data show for men with hypogonadism who lose weight on GLP-1 medicines.
If you are prescribed testosterone replacement (whether gel, patch, injection or oral) and you want to start semaglutide for weight management, the main steps are straightforward. Tell your GP and the prescriber reviewing your semaglutide consultation about your existing treatment. That includes the form, dose and how long you have been on it.
For injectable testosterone, the interaction concern is minimal from an absorption standpoint. For oral forms, your prescriber may recommend taking testosterone at least 30 minutes before your semaglutide dose or timing it separately, though specific scheduling should follow their clinical judgement rather than a general rule.
If cost context is part of your thinking as you weigh up private treatment options, our guide to Wegovy pricing in the UK explains what an honest private price typically includes. On questions about other combination queries, you might also find the pages on taking semaglutide and liraglutide together and semaglutide alongside MOTS-C useful for understanding how prescribers think about concurrent therapies.
What actually arrives from nume, sorry, from a registered pharmacy: a plain, unbranded box via DPD, trackable to the hour, containing your Wegovy pen exactly as licensed and dispensed. The clinical review happens before that box is even packed. A real prescriber, not an automated process, reads your consultation answers the same day you submit them. That matters for any patient with a pre-existing therapy like testosterone, because the nuance of your situation is exactly what same-day clinical review is for.
You can read more about weight-loss treatments available privately in the UK and how they compare, or explore questions about other semaglutide combination queries that our prescribers are often asked. For anything specific to your own circumstances, speaking directly to a clinician is the only route to a reliable answer.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.